EGFR and adenocarcinoma: In contrast to these previous studies, the frequency of EGFR-mutant tumors in this study was assessed among patients selected on the basis of clinico-pathologic characteristics (e.g., patients with adenocarcinomas and/or non-smokers were more likely to have an EGFR test).